This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
LEO Pharma A/S
Drug Names(s): FK506 (ointment), tacrolimus ointment/cream, protopy
Description: Protopic (tacrolimus ointment) is a calcineurin inhibitor and function as an immunosuppressant. It inhibits T-lymphocyte activation by first binding to an intracellular protein FKBP-12, by forming a complex with FKBP-12, calcium, calmodulin, and calcineurin, inhibiting the phosphatase activity of calcineurin. This is believed to prevent the formation of lymphokines (IL-2, gamma interferon).
Deal Structure: In January 2004, Fujisawa and Roche entered intoan exclusive partnership agreement to expand the global presence of Protopic for eczema. Under the agreement Roche will be responsible for the exclusive distribution and promotion of Protopic in Mexico, Brazil, Chile, Colombia,Ecuador, Peru, Venezuela, Central America, and the Caribbean.
On April 1, 2005, Astellas Pharma was formed from a merger between Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical.
In December 2010, Maruho and Astellas announced that the companies have agreed that Astellas will assign detailing/promotional activities for Protopic in Japan to Maruho on April 1, 2011 and thereafter will transfer its distribution right in Japan to Maruho on April 1, 2014.
Astellas and LEO
In November 2015, Astellas Pharma announced that Astellas and LEO Pharma entered into an Asset Purchase Agreement, under which Astellas will transfer its global dermatology business to LEO Pharma for 675 million. Under...See full deal structure in Biomedtracker
Partners: Roche Holding AG Maruho Co., Ltd. Astellas Pharma, Inc.
Additional information available to subscribers only: